PDF(Pubmed)
Abstract：
BACKGROUND: Current standard treatments for patients with recurrent cervical cancer are not very effective and are associated with severe toxicity. Recently, the rational approach for the discovery of new therapies for cervical cancer is based on the alterations in the molecular biology of cancer cells. One of the emerging molecular changes in cancer cells is the aberrant expression of cytochrome P450 1B1 (CYP1B1). This unique enzyme has been reported to be selectively overexpressed in several cancers.
OBJECTIVE: The aim of this study was to examine CYP1B1 expression in cervical cancers and to assess the enzyme\'s relationship with several clinicopathological features.
METHODS: Immunohistochemistry was performed to examine CYP1B1 expression in 100 patient samples with cervical cancer and 10 patient samples with normal healthy cervical tissues.
RESULTS: CYP1B1 was expressed in the majority of the cervical cancer samples (91/100, 91.0%) but not in normal healthy cervical samples. The difference in the expression of CYP1B1 between healthy and tumorous cervical tissues was significant (P=.01). Moreover, the frequency of CYP1B1 expression was found to be significantly higher in patients with advanced grades of the disease (P=.03) and in patients having metastasis to the lymph nodes (P=.01). Surprisingly, there was a significantly higher expression of CYP1B1 in patients with a high prevalence of human papilloma virus 16/18 (P=.04).
CONCLUSIONS: The differential profile of CYP1B1 expression between cervical cancer tissues and normal cervical tissues suggests that CYP1B1 may be used as a target for future therapeutic exploitations.
OBJECTIVE: The aim of this study was to examine CYP1B1 expression in cervical cancers and to assess the enzyme\'s relationship with several clinicopathological features.
METHODS: Immunohistochemistry was performed to examine CYP1B1 expression in 100 patient samples with cervical cancer and 10 patient samples with normal healthy cervical tissues.
RESULTS: CYP1B1 was expressed in the majority of the cervical cancer samples (91/100, 91.0%) but not in normal healthy cervical samples. The difference in the expression of CYP1B1 between healthy and tumorous cervical tissues was significant (P=.01). Moreover, the frequency of CYP1B1 expression was found to be significantly higher in patients with advanced grades of the disease (P=.03) and in patients having metastasis to the lymph nodes (P=.01). Surprisingly, there was a significantly higher expression of CYP1B1 in patients with a high prevalence of human papilloma virus 16/18 (P=.04).
CONCLUSIONS: The differential profile of CYP1B1 expression between cervical cancer tissues and normal cervical tissues suggests that CYP1B1 may be used as a target for future therapeutic exploitations.
摘要：
背景：目前针对复发性宫颈癌患者的标准治疗方法并不十分有效，并且与严重的毒性相关。最近,发现宫颈癌新疗法的合理方法是基于癌细胞分子生物学的改变。癌细胞中新兴的分子变化之一是细胞色素P4501B1（CYP1B1）的异常表达。据报道，这种独特的酶在几种癌症中选择性地过度表达。
目的：本研究的目的是检测CYP1B1在宫颈癌中的表达，并评估该酶与几种临床病理特征的关系。
方法：采用免疫组织化学方法检测100例宫颈癌患者样本和10例正常健康宫颈组织样本中CYP1B1的表达。
结果：CYP1B1在大多数宫颈癌样本中表达（91/100，91.0％），但在正常健康宫颈样本中不表达。CYP1B1在健康和肿瘤宫颈组织中的表达差异有统计学意义（P=0.01）。此外，发现CYP1B1表达频率在疾病晚期患者(P=.03)和淋巴结转移患者(P=.01)中显著较高.令人惊讶的是,CYP1B1在人乳头瘤病毒16/18高患病率患者中的表达明显更高(P=.04).
结论：CYP1B1在宫颈癌组织和正常宫颈组织之间的表达差异表明CYP1B1可能作为未来治疗开发的靶点。
目的：本研究的目的是检测CYP1B1在宫颈癌中的表达，并评估该酶与几种临床病理特征的关系。
方法：采用免疫组织化学方法检测100例宫颈癌患者样本和10例正常健康宫颈组织样本中CYP1B1的表达。
结果：CYP1B1在大多数宫颈癌样本中表达（91/100，91.0％），但在正常健康宫颈样本中不表达。CYP1B1在健康和肿瘤宫颈组织中的表达差异有统计学意义（P=0.01）。此外，发现CYP1B1表达频率在疾病晚期患者(P=.03)和淋巴结转移患者(P=.01)中显著较高.令人惊讶的是,CYP1B1在人乳头瘤病毒16/18高患病率患者中的表达明显更高(P=.04).
结论：CYP1B1在宫颈癌组织和正常宫颈组织之间的表达差异表明CYP1B1可能作为未来治疗开发的靶点。
